Originally published at: When healthcare M&A hits the cold chain - FreightWaves
The $4.8 billion acquisition of Amicus Therapeutics by BioMarin is, on its surface, a familiar healthcare story: portfolio expansion, accelerated revenue growth, and a stronger foothold in the rare ■■■■■■■ market. But beneath the financial headlines sits a less visible and increasingly critical reality. For supply chain and cold chain professionals, deals like this are…